Menu
Back to Journals » ImmunoTargets and Therapy » Volume 2
Update on immunopathogenesis and immunotherapy in multiple sclerosis
Received 12 November 2012
Accepted for publication 9 March 2013
Published 26 April 2013 Volume 2013:2 Pages 21—30
DOI https://doi.org/10.2147/ITT.S31813
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Rebecca C Selter,1 Bernhard Hemmer1–3
1Department of Neurology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; 2Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; 3Competence Network on Multiple Sklerosis, Munich, Germany
Abstract: Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Both genetic and environmental factors are believed to contribute to the pathogenesis of the disease. Histopathological findings suggest that multiple sclerosis is an immune-mediated disease, involving both the cellular and humoral immune systems. Within the last 20 years, several disease-modifying therapies for the treatment of multiple sclerosis were established. Moreover, promising new substances are currently being tested in clinical trials and will likely broaden the therapeutic opportunities available within the upcoming years.
Keywords: multiple sclerosis, immunopathogenesis, disease-modifying therapy
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.